Stock Earnings

Question 1

Quels sont les états financiers clés de BioCryst Pharmaceuticals Inc ?

Accepted Answer

Selon le dernier état financier (Form-10K), BioCryst Pharmaceuticals Inc a un total d'actifs de $490, un bénéfice net loss de $-88

Question 2

Quels sont les ratios financiers clés pour BCRX ?

Accepted Answer

Le ratio de liquidité de BioCryst Pharmaceuticals Inc est 0.5, la marge nette est -19.55, les ventes par action sont de $2.17.

Question 3

Comment les revenus de BioCryst Pharmaceuticals Inc sont-ils répartis par segment ou géographie ?

Accepted Answer

BioCryst Pharmaceuticals Inc largest revenue segment is Oral Small-molecule and Injectable Protein Therapeutics, at a revenue of 450,712,000 in the most earnings release.For geography, United States is the primary market for BioCryst Pharmaceuticals Inc, at a revenue of 385,961,000.

Question 4

BioCryst Pharmaceuticals Inc est-elle rentable ?

Accepted Answer

no, selon les derniers états financiers, BioCryst Pharmaceuticals Inc a un bénéfice net loss de $-88

Question 5

BioCryst Pharmaceuticals Inc a-t-elle des passifs ?

Accepted Answer

yes, BioCryst Pharmaceuticals Inc a un passif de 966

Question 6

Combien d'actions en circulation BioCryst Pharmaceuticals Inc a-t-elle ?

Accepted Answer

BioCryst Pharmaceuticals Inc a un total d'actions en circulation de 208.54

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	557	450	331	270	157	17
Revenue Growth (YoY)	46%	36%	23%	72%	824%	-65%
Cost of Revenue	16	12	4	6	7	1
Gross Profit	540	438	326	264	149	16
Selling, General & Admin	315	266	213	159	118	67
Research & Development	171	174	215	253	208	123
Operating Expenses	486	440	428	412	327	190
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-32	-86	-226	-244	-181	-182
Income Tax Expense	3	1	0	2	2	--
Net Income	-35	-88	-226	-247	-184	-182
Net Income Growth	-76%	-61%	-9%	34%	1%	69%
Shares Outstanding (Diluted)	219.88	206.69	192.19	185.9	179.1	167.3
Shares Change (YoY)	7%	8%	3%	4%	7%	45%
EPS (Diluted)	-0.17	-0.43	-1.17	-1.33	-1.03	-1.09
EPS Growth	-75%	-64%	-11%	28.99%	-6%	16%
Free Cash Flow	0	-53	-97	-163	-144	-135
Free Cash Flow Per Share	0	-0.25	-0.5	-0.87	-0.8	-0.8
Gross Margin	96.94%	97.33%	98.48%	97.77%	94.9%	94.11%
Operating Margin	9.69%	-0.44%	-30.81%	-54.81%	-112.73%	-1,023.52%
Profit Margin	-6.28%	-19.55%	-68.27%	-91.48%	-117.19%	-1,070.58%
Free Cash Flow Margin	0%	-11.77%	-29.3%	-60.37%	-91.71%	-794.11%
EBITDA	55	-1	-101	-147	-177	-174
EBITDA Margin	9.87%	-0.22%	-30.51%	-54.44%	-112.73%	-1,023.52%
D&A For EBITDA	1	1	1	1	0	0
EBIT	54	-2	-102	-148	-177	-174
EBIT Margin	9.69%	-0.44%	-30.81%	-54.81%	-112.73%	-1,023.52%
Effective Tax Rate	-9.37%	-1.16%	0%	-0.81%	-1.1%	--

BioCryst Pharmaceuticals Inc (BCRX) Price

BCRX Stock Price Chart

BCRX Income

Follow-Up Questions